Home/Pipeline/Colorectal Cancer Biomarkers

Colorectal Cancer Biomarkers

Colorectal Cancer

DiscoveryActive

Key Facts

Indication

Colorectal Cancer

Phase

Discovery

Status

Active

Company

Paradise Genomics

About Paradise Genomics

Paradise Genomics is a private, pre-revenue diagnostics company leveraging over 30 years of collective founder experience in genomics to discover novel biomarker signatures. The company emerged from GenUs BioSystems, a contract lab with a strong track record, and now aims to validate and commercialize its discoveries through partnerships with diagnostic and pharmaceutical companies. Its core value proposition is a proprietary bioinformatics process that claims unmatched sensitivity and precision in unlocking a unique region of the transcriptome for actionable genomic data.

View full company profile

Therapeutic Areas

Oncology Psychiatry Pain Management Gastroenterology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active